Estimating the Time to Benefit for Therapies in Heart Failure with Reduced Ejection Fraction: A Case Study of Sacubitril-Valsartan Using Reconstructed Data from a Randomized Controlled Trial
ConclusionUsing multiple approaches, the earliest benefit of sacubitril-valsartan compared to enalapril in stable HFrEF was found at about 1 month after initiation.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
More News: Cardiology | Cardiovascular | Diovan | Enalapril | Geriatrics | Heart | Heart Failure | Statistics | Study